[Sentinel lymph node biopsy in cutaneous non-melanoma malignancies].
OBJECTIVE
To assess the feasibility of the Sentinel lymph node biopsy (SLNB) technique in cutaneous non-melanoma malignancies.


METHODS
Nine patients were retrospectively evaluated performing a scintigraphy with 99mTc-nanocolloid. On the day of the surgery, an initial dynamic study and static images were obtained. The first drainage station visualized was considered the sentinel node (SLN). The SLN position was marked on the skin and after a correct localization in the surgical field with a gamma probe the SLN was obtained. Patients of this study have been followed up for 8 to 48 months.


RESULTS
Lymphoscintigraphy detected the sentinel node in 88,8 % of our studies (the SLN was not observed in a patient with a Merkel's tumour on the back). The SLN was identified intraoperatively in those patients with positive imaging. Those cases without scintigraphic demonstrated migration were also not found intraoperatively. Histopathological analysis of the SLN showed non metastatic disease and none patient developed metastases or local recurrence in the monitoring period.


CONCLUSIONS
Sentinel node biopsy can be applied to certain cutaneous non-melanoma malignancies. In patients with unclear drainage and to avoid unnecessary lymphadenectomy, the technique offers clear advantages. In our study the SLN analysis was related to the clinical progress. A large number of patients should be examined to truly assess the benefit of this technique in this kind of malignancies and to determinate when the technique must be performed.
Cózar
M P
MP
Servicio de Medicina Nuclear, Hospital Clínico Universitario de Valencia. cozar_mar@gva.es
Ferrer-Rebolleda
J
J
Redal
M C
MC
Moreno
A
A
Tortajada
L
L
Casáns
I
I
Romero
C
C
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary; D002280:Basal Cell Carcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary; D015266:Carcinoma, Merkel Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary; D002648:Child; D018223:Dermatofibrosarcoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy / Q000706:statistics & numerical data; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology*; D013668:Technetium Tc 99m Aggregated Albumin
D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; C083602:technetium Tc 99m nanocolloid